PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
15.50%
EBIT growth below 50% of TRAW's 100.00%. Michael Burry would suspect deeper competitive or cost structure issues.
16.24%
Positive operating income growth while TRAW is negative. John Neff might view this as a competitive edge in operations.
12.65%
Positive net income growth while TRAW is negative. John Neff might see a big relative performance advantage.
12.55%
Positive EPS growth while TRAW is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
12.55%
Positive diluted EPS growth while TRAW is negative. John Neff might view this as a strong relative advantage in controlling dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-72.30%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-72.30%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-364.91%
Negative 10Y OCF/share CAGR while TRAW stands at 77.68%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-364.91%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-364.91%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-5621.33%
Negative 10Y net income/share CAGR while TRAW is at 98.31%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-5621.33%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-5621.33%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
-1604.85%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-1604.85%
Negative 5Y equity/share growth while TRAW is at 10162.80%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-1604.85%
Negative 3Y equity/share growth while TRAW is at 7609.85%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-43.54%
Negative asset growth while TRAW invests at 81849.33%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-8.62%
We have a declining book value while TRAW shows 59775.48%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
6.57%
Debt growth of 6.57% while TRAW is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.
No Data
No Data available this quarter, please select a different quarter.
-21.27%
We cut SG&A while TRAW invests at 61301.60%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.